2023-06-26 22:42:37
A view of the headquarters of Samil Pharmaceutical located in Hyoryeong-ro, Seocho-gu, Seoul.
[헬스코리아뉴스 / 이한울] Samil Pharmaceutical is rushing toward 200 billion won in annual sales for the first time in history with the expansion of its central nervous system (CNS) business through the acquisition of Sandoz Korea products.
According to the industry on the 27th, as Sandoz Korea closed its domestic business on the 30th, Samil Pharmaceutical will begin distributing Sandoz Korea products in Korea from the 1st of next month.
Established in 2003, Sandoz Korea is a subsidiary of Novarti that distributes generic drugs and biosimilars. Hand it over to Samil Pharmaceutical.
Currently, Sandoz Korea is distributing 41 items in Korea. Major items include chronic disease, anticancer drugs, and CNS drugs, such as Amlodipine Tab., Atorvastatin Tab., Paclitaxel Inj., and Zolpidem Tab.
Samil Pharmaceutical plans to further strengthen the recently expanding CNS field. In order to expand the CNS lineup in 2021, the company established a new CNS division for sales of existing neurology teams and psychiatric products. Since the new products inherited from Sandoz utilize the existing sales network, it is unlikely that there will be any difficulties in sales.
The industry predicts that Samil Pharmaceutical will easily exceed 200 billion won in sales this year as it starts selling Sandoz Korea products. Samil Pharmaceutical recorded sales of 179.6 billion won last year, breaking a record high.
Following the CNS field, it is also strengthening its main focus, the ophthalmology business. Early this year, it launched ‘Reba-K’ (rebamipide), an eye drop for treating dry eye syndrome, and started domestic sales of ‘Amelibu’ (ranibizumab), a macular degeneration treatment developed by Samsung Bioepis.
Genentech’s macular degeneration treatment ‘Lucentis’, the original product of ‘Amelibu’, maintains annual sales of 35 billion won in the domestic macular degeneration market.
In addition, it is expected to solidify its image as a professional pharmaceutical company in the ophthalmology and CNS prescription market as it has also acquired Sandoz Korea’s CNS treatment.
An official from Samil Pharmaceutical said in a phone call with Health Korea News on the 26th, “The sales of Sandoz Korea’s treatment products prove that we are solidifying our position as a trusted partner from global companies.” We expect that we will be able to drive continued growth in sales and operating profit.”
© Health Korea News Unauthorized reproduction and redistribution prohibited
1687822883
#Samil #Pharmaceutical #rushing #billion #won #sales #Sandoz #Korea
